BIO-TECHNE
TECH· Manufacturing· Fiscal year ends in June
Kim Kelderman is the CEO of BIO-TECHNE and was paid $8.2M in FY2025 (Jun).
Executives5
See all- 1Kim KeldermanPresident and CEOFY2025
- 2James HippelExecutive Vice President and CFOFY2025
- 3William GeistPresident, Protein SciencesFY2025
- 4Matthew McManusPresident, Diagnostics and Spatial BiologyFY2025
- 5Shane BohnenSenior Vice President and General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBIO-TECHNE paid its 5 named executives $23.1M in total in FY2025 (Jun). CEO Kim Kelderman was paid $8.2M of that.
| Name | |||
|---|---|---|---|
| Kim KeldermanPresident and CEO | Not disclosed | ||
| James HippelExecutive Vice President and CFO | Not disclosed | ||
| William GeistPresident, Protein Sciences | |||
| Matthew McManusPresident, Diagnostics and Spatial Biology | |||
| Shane BohnenSenior Vice President and General Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Jun) proxy of BIO-TECHNE names 18 peer companies for pay. Among BIO-TECHNE and these peers, CEO pay was the lowest of 4 and total shareholder return was 2nd highest of 4.
4th highest of 4in BIO-TECHNE and its pay peers, FY2025 (Jun) by CEO pay:
2nd highest of 4in BIO-TECHNE and its pay peers, FY2025 (Jun) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Charles KummethDirector · 10 yr on the boardIndependent—Paid as an executive
- Joseph D. Keegan, Ph.D.Director · 6 yr on the boardIndependentCompensation—Paid as an executive
- Julie L. BushmanDirector · 3 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
The board of the latest proxy (FY2023).
Shared directors
- Phillips 66Julie L. Bushman1 shared
Activity
Filings28
See all| Current report | 8-K | Sep 23, 2026 | — |
| Annual report | 10-K | Aug 24, 2026 | FY2026 |
| Current report | 8-K | Jun 26, 2026 | — |
| Current report | 8-K | Feb 11, 2026 | — |
| Current report | 8-K | Nov 5, 2025 | — |
| Proxy statement | DEF 14A | Sep 19, 2025 | FY2025 |
